Biomark Diagnostics Inc. (BMKDF)

Market Cap	38.34M +56.4%
Revenue (ttm)	42.83K -61.2%
Net Income	-1.06M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4003
Previous Close	0.4003
Day's Range	0.4003 - 0.4003
52-Week Range	0.2120 - 0.5044
Beta	-0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: BMKDF

Financial Performance

In fiscal year 2026, Biomark Diagnostics's revenue was 59,787, a decrease of -61.23% compared to the previous year's 154,216. Losses were -1.48 million, -23.35% less than in 2025.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 11, 2026

Data Sources Report a data error